We noticed that the ruthenium-phloretin complex treatment module effectively decreased NF-κB intensity in the colon carcinoma cells (Figure 5(e), A–G), hence denoting that ruthenium-phloretin treatment influences the inflammatory pathways in colon cancer. The gene discussed is NFKB1; the disease is colon carcinoma.